Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT02966587
Phase
PHASE2
Status
Withdrawn

Conditions

  • Castration Levels of Testosterone
  • Hormone-Resistant Prostate Cancer
  • Microsatellite Instability

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — BIOLOGICAL
    Given IV
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies

Study Details

This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date
May 15, 2018
Status verified
Jan 2018
Primary completion
May 15, 2023
Completion
May 15, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (durvalumab)
    Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Response rate to durvalumab defined according to modified RECIST 1.1 criteria or a reduction in PSA level >= 50% [ Time Frame: Up to 3 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109-

Find similar trials in Seattle, WA

By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies